Effect of HBIG on blocking motherª²toª²infant transmission of HBV

    CUI Hengª²Chun1, YAN Yongª²Ping1, SHAO Zhongª²Jun1, XU Deª²Zhong1, MEN Ke1, XU Jianª²Qiu2, LI Jun2

    1Department of Epidemiology, School of Preventive Medicine, Fourth Military Medical University, Xi¬ðan 710033£¬China, 2Department of Obstetrics, Maternal and Children Health Hospital of Shaanxi Province, Xi¬ðan 710003, China

    ¡¾Abstract¡¿ AIM: To evaluate the blocking effect of hepatitis B immunoglobulin (HBIG) administrated to HBsAg positive pregnant women during late pregnancy and immune reagents (HBIG together with HBV vaccine) to their neonates on motherª²toª²infant transmission of HBV and its chronicity. METHODS: Each infant in the historical control group (n=205) was only immunized with 3 doses of plasmaª²derived vaccine routinely, while each pregnant woman in the HBIG group (n=213) was given 200 u HBIG intramuscularly every 4 weeks from 28th week of gestation and each of their infants was injected intramuscularly with HBIG 200 u at birth and 15 d after birth and then with 3 doses of recombinant yeastª²derived hepatitis B vaccine routinely. All infants were followed up to observe the change of serum HBsAg. A historical control clinical trial was performed to evaluate the blocking effect of HBIG injected to mothers and their newborns on motherª²toª²infant HBV transmission and its chronicity. RESULTS: The rates of intrauterine HBV infection, seroconversion to HBsAg positivity in infants during followª²up, HBV infection chronicity were 5.34%, 5.15%, 87.5% respectively in control group, and 5.26% ......